Contact
Please use this form to send email to PR contact of this press release:
Loxo Oncology TRK Inhibitor LOXO-101 Demonstrates Promising Clinical Activity and Safety in Phase 1 Trial
TO:
Please use this form to send email to PR contact of this press release:
Loxo Oncology TRK Inhibitor LOXO-101 Demonstrates Promising Clinical Activity and Safety in Phase 1 Trial
TO: